Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,123 stopped studies mapped to Non-Small Cell Carcinoma and descendants · 90% state a reason
Over the 1,123 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06075615 | A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has… | — | withdrawn | Oct 10, 2023 | Pfizer | Sponsor Decision | Sponsor / business decision |
| NCT04474613 | Liquid Biopsy to Reduce Time to Treatment for Advanced Nonsquamous NSCLC Diagnosed at… | N/A | terminated | Jul 17, 2020 | Case Comprehensive Cancer Center | Slow accrual | Enrollment / accrual |
| NCT03371381 | An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes… | Phase 1 / Phase 2 | terminated | Dec 13, 2017 | Janssen Research & Development, LLC | Development of JNJ-64041757 in combination with nivolumab discontinued due to lack of clinical… | Efficacy / futility |
| NCT02592967 | Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria… | Phase 1 | terminated | Oct 30, 2015 | Janssen Research & Development, LLC | Development of JNJ-64041757 discontinued due to lack of efficacy. No further follow up data will be… | Efficacy / futility |
| NCT02887521 | Pulmonary Rehabilitation Before Lung Cancer Resection | Phase 3 | terminated | Sep 2, 2016 | Alliance for Clinical Trials in Oncology | Poor accrual | Enrollment / accrual |
| NCT03705403 | IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study(IMMUNOSABR2) | Phase 2 | terminated | Oct 15, 2018 | Maastricht University Medical Center | This trial is not transitioning to the Clinical Trial Regulation (CTR) EU No 536/2014. | Other (stated, no rule matched) |
| NCT03948763 | A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) | Phase 1 | terminated | May 14, 2019 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT04916236 | Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers(SHERPA) | Phase 1 | terminated | Jun 7, 2021 | The Netherlands Cancer Institute | Due to a lack of safety and efficacy. | Safety / toxicity |
| NCT06681870 | A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors | Phase 1 | withdrawn | Nov 8, 2024 | Astellas Pharma Global Development, Inc. | A business decision was made to not initiate this study. | Sponsor / business decision |
| NCT04856176 | A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with… | Phase 2 | terminated | Apr 23, 2021 | Tufts Medical Center | Futility | Efficacy / futility |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Phase 1 / Phase 2 | terminated | Aug 15, 2022 | Aminex Therapeutics, Inc. | Required re-formulation of DFMO from IV to capsule to maintain safety | Safety / toxicity |
| NCT04364048 | Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III… | Phase 2 | terminated | Apr 27, 2020 | Rachel Sanborn | Study enrollment was halted due to pandemic-related slow accrual | COVID-19 / pandemic |
| NCT04889066 | Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small… | Phase 2 | withdrawn | May 17, 2021 | University of Texas Southwestern Medical Center | Project Never Initiated since sponsor stopped support for the trial- no human subjects were… | Enrollment / accrual |
| NCT03549000 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in… | Phase 1 | terminated | Jun 7, 2018 | Novartis Pharmaceuticals | After review of data which showed low likelihood of efficacy in these patients Novartis decided to… | Safety / toxicity |
| NCT05094544 | Pre-Operative Immuno-Modulatory SBRT (POIMS Trial): A Pilot Trial in Early Stage NSCLC(POIMS) | N/A | withdrawn | Oct 26, 2021 | University of Kansas Medical Center | No participants enrolled | Enrollment / accrual |
| NCT05375084 | SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small… | Phase 1 | terminated | May 16, 2022 | Navire Pharma Inc., a BridgeBio company | Business reasons | Sponsor / business decision |
| NCT05480865 | SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid…(Argonaut) | Phase 1 | terminated | Jul 29, 2022 | Navire Pharma Inc., a BridgeBio company | Business Reasons | Sponsor / business decision |
| NCT04939701 | Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1… | Phase 1 / Phase 2 | terminated | Jun 25, 2021 | Astellas Pharma Global Development, Inc. | The comprehensive assessment of other studies indicated the lack of significant monotherapy… | Other (stated, no rule matched) |
| NCT02588261 | A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With…(SOLAR) | Phase 3 | terminated | Oct 27, 2015 | Astellas Pharma Global Development, Inc. | Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies | Enrollment / accrual |
| NCT04515979 | Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung… | Phase 2 | terminated | Aug 17, 2020 | MedPacto, Inc. | This is because Medpacto decided to modify its development strategy as the business and development… | Sponsor / business decision |
| NCT02495233 | A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor… | Phase 1 / Phase 2 | terminated | Jul 13, 2015 | Astellas Pharma Global Development, Inc. | Study terminated due to adverse events related to the combination therapy | Safety / toxicity |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT02500927 | A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase… | Phase 2 | terminated | Jul 17, 2015 | Astellas Pharma Inc | Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies. | Enrollment / accrual |
| NCT03082300 | A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring… | Phase 1 | terminated | Mar 17, 2017 | Astellas Pharma Global Development, Inc. | Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies. | Enrollment / accrual |
| NCT06068153 | AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C…(AMBER) | Phase 2 | withdrawn | Oct 5, 2023 | ETOP IBCSG Partners Foundation | In view of the recent developments in the field (the increasing number of trials with new KRAS… | Other (stated, no rule matched) |
| NCT01217411 | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating… | Phase 1 / Phase 2 | terminated | Oct 8, 2010 | National Cancer Institute (NCI) | Other - Protocol moved to Administratively Complete | Other (stated, no rule matched) |
| NCT03166631 | A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in… | Phase 1 | terminated | May 25, 2017 | Boehringer Ingelheim | Not due to safety reasons. | Safety / toxicity |
| NCT02192697 | An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have… | Phase 1 / Phase 2 | terminated | Jul 17, 2014 | Astellas Pharma Inc | Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies. | Enrollment / accrual |
| NCT04287894 | Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to…(Induction) | Phase 1 | terminated | Feb 27, 2020 | The Netherlands Cancer Institute | Based on initially defined safety rules not continued with expansion phase of study (too much… | Safety / toxicity |
| NCT06448364 | A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When…(LTbR) | Phase 1 | terminated | Jun 7, 2024 | Pfizer | Strategic business decision | Sponsor / business decision |
| NCT04795713 | Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 | Phase 1 | terminated | Mar 12, 2021 | Molecular Templates, Inc. | Terminated by Sponsor | Other (stated, no rule matched) |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With… | Phase 1 | terminated | Sep 13, 2023 | Molecular Templates, Inc. | Sponsor Termination | Other (stated, no rule matched) |
| NCT04866017 | A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent… | Phase 3 | terminated | Apr 29, 2021 | BeiGene | This decision was conducted by the sponsor and not driven by safety concerns as no new safety… | Safety / toxicity |
| NCT04791215 | Circulating Tumor DNA Alterations in Non-small Cell Lung Cancer Patients Treated With… | — | terminated | Mar 10, 2021 | Columbia University | Low accrual | Enrollment / accrual |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors…(PDL1x41BB) | Phase 1 | terminated | Jan 18, 2019 | Inhibrx Biosciences, Inc | Program terminated due to lack of meaningful efficacy signal. | Efficacy / futility |
| NCT04987281 | Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in… | Phase 2 | withdrawn | Aug 3, 2021 | M.D. Anderson Cancer Center | 0 ACTUAL Enrollment must have Overall Recruitment | Enrollment / accrual |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | Phase 2 | terminated | Aug 19, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT01088906 | Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced…(Phalcis) | Phase 2 | terminated | Mar 17, 2010 | Spanish Lung Cancer Group | No safety reasons. Low recruitment. | Safety / toxicity |
| NCT05492045 | A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | terminated | Aug 8, 2022 | InventisBio Co., Ltd | Adjustment of drug development strategy. | Sponsor / business decision |
| NCT03996473 | Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting… | Phase 1 | terminated | Jun 24, 2019 | Bayer | LPLV reached on 30Jan2023. Study was closed early for feasibility reasons related to enrollment of… | Safety / toxicity |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and… | Phase 2 | terminated | Jul 5, 2017 | Novartis Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT03447769 | Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult…(Canopy-A) | Phase 3 | terminated | Feb 27, 2018 | Novartis Pharmaceuticals | Upon review of the primary analysis results, the benefit-risk was assessed by the Steering… | Safety / toxicity |
| NCT04139317 | Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in… | Phase 2 | terminated | Oct 25, 2019 | Novartis Pharmaceuticals | Sponsor decision to terminate due to the lack of tolerability observed in patients treated with… | Sponsor / business decision |
| NCT04323436 | Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14… | Phase 2 | terminated | Mar 26, 2020 | Novartis Pharmaceuticals | Study termination based on sponsor decision due to lack of tolerability observed with capmatinib… | Sponsor / business decision |
| NCT05718297 | Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell…(BOUNCE) | Phase 2 | withdrawn | Feb 8, 2023 | ETOP IBCSG Partners Foundation | Despite our efforts, the trial faced challenges like a longer activation period and slower accrual.… | Enrollment / accrual |
| NCT05397171 | A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants… | Phase 1 / Phase 2 | terminated | May 31, 2022 | AstraZeneca | This study was terminated early as per protocol Section 4.4, based on overall risk-benefit profile… | Safety / toxicity |
| NCT06427369 | An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer | Phase 1 | withdrawn | May 23, 2024 | Roswell Park Cancer Institute | prioritization | Other (stated, no rule matched) |
| NCT03989050 | Immunogenicity and Safety of Pneumococcal Vaccination in Patients Treated With Immune…(SPICE) | — | withdrawn | Jun 18, 2019 | University of Cologne | Administrative reasons | Other (stated, no rule matched) |
| NCT04965818 | Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced… | Phase 1 | terminated | Jul 16, 2021 | Taiho Oncology, Inc. | Strategic decision by sponsor. | Sponsor / business decision |
| NCT05757843 | Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab | Phase 2 | withdrawn | Mar 7, 2023 | Indiana University | Unable to identify patients who meet eligibility requirements of tissue needed for analysis. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Feb 7, 2025source: clinicaltrials